DB:PGP

Stock Analysis Report

Executive Summary

Progenics Pharmaceuticals, Inc., an oncology company, develops, manufactures, and commercializes pharmaceutical products and other technologies to target, diagnose, and treat cancer in the United States and internationally.

Rewards

Revenue is forecast to grow 37.66% per year

Risk Analysis

Has less than 1 year of cash runway

Currently unprofitable and not forecast to become profitable over the next 3 years

Shareholders have been diluted in the past year



Snowflake Analysis

Limited growth with imperfect balance sheet.


Similar Companies

Share Price & News

How has Progenics Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: PGP has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

-1.4%

PGP

-1.8%

DE Biotechs

0.1%

DE Market


1 Year Return

4.4%

PGP

7.2%

DE Biotechs

14.1%

DE Market

Return vs Industry: PGP underperformed the German Biotechs industry which returned 6.8% over the past year.

Return vs Market: PGP underperformed the German Market which returned 15.1% over the past year.


Shareholder returns

PGPIndustryMarket
7 Day-1.4%-1.8%0.1%
30 Day3.4%-2.9%0.2%
90 Day-10.4%5.8%3.3%
1 Year4.4%4.4%7.5%7.2%17.6%14.1%
3 Year-55.7%-55.7%42.8%41.2%14.8%4.8%
5 Year-22.7%-22.7%11.6%9.3%22.2%5.4%

Price Volatility Vs. Market

How volatile is Progenics Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Progenics Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

7.28x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate PGP's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate PGP's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: PGP is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: PGP is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate PGP's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: PGP is overvalued based on its PB Ratio (7.1x) compared to the DE Biotechs industry average (3.5x).


Next Steps

Future Growth

How is Progenics Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

46.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: PGP is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: PGP is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: PGP is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: PGP's revenue (37.7% per year) is forecast to grow faster than the German market (5% per year).

High Growth Revenue: PGP's revenue (37.7% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: PGP is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has Progenics Pharmaceuticals performed over the past 5 years?

-42.7%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: PGP is currently unprofitable.

Growing Profit Margin: PGP is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: PGP is unprofitable, and losses have increased over the past 5 years at a rate of -42.7% per year.

Accelerating Growth: Unable to compare PGP's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: PGP is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.7%).


Return on Equity

High ROE: PGP has a negative Return on Equity (-128.68%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Progenics Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: PGP's short term assets ($75.8M) exceed its short term liabilities ($20.1M).

Long Term Liabilities: PGP's short term assets ($75.8M) exceed its long term liabilities ($54.0M).


Debt to Equity History and Analysis

Debt Level: PGP's debt to equity ratio (73.2%) is considered high.

Reducing Debt: Insufficient data to determine if PGP's debt to equity ratio has reduced over the past 5 years.


Balance Sheet

Inventory Level: PGP has a low level of unsold assets or inventory.

Debt Coverage by Assets: PGP's debt is covered by short term assets (assets are 1.9x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: PGP has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: PGP has less than a year of cash runway if free cash flow continues to reduce at historical rates of -22% each year


Next Steps

Dividend

What is Progenics Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.3%markettop25%3.6%industryaverage1.0%forecastin3Years0%

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate PGP's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate PGP's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if PGP's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if PGP's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of PGP's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.5yrs

Average management tenure


CEO

David Mims (56yo)

0.3yrs

Tenure

0

Mr. David W. Mims has been an Interim Chief Executive Officer of Progenics Pharmaceuticals, Inc. since November 15, 2019 and served as Director since November 8, 2019. Mr. Mims has also served as a member  ...


Leadership Team

NamePositionTenureCompensationOwnership
Patrick Fabbio
Executive VP & CFO4.3yrsUS$974.15k0.029% $108.9k
Benedict Osorio
Chief Operating Officer0.9yrsUS$967.41k0.025% $92.3k
Vivien Wong
Executive Vice President of Development0yrsUS$1.02m0.0048% $17.9k
Bryce Tenbarge
Senior Vice President of Commercial1.8yrsUS$869.06kno data
David Mims
Interim CEO & Director0.3yrsno datano data
Melissa Downs
Senior Manager of Investor Relations0yrsno datano data
Jessica Jensen
Senior Vice President of Clinical Development1.8yrsno datano data
Asha Das
Chief Medical Officer1.1yrsno datano data
Huw Jones
Vice President of Commercial0yrsno datano data

1.5yrs

Average Tenure

55yo

Average Age

Experienced Management: PGP's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
David Mims
Interim CEO & Director0.3yrsno datano data
John Mendelsohn
Member of Cancer Scientific Advisory Board0yrsno datano data
Stephen Goff
Chairman of The Virology Scientific Advisory Board28.8yrsUS$119.76kno data
Robin Weiss
Member of Virology Scientific Advisory Board0yrsno datano data
Sherie Morrison
Member of Virology Scientific Advisory Board0yrsno datano data
Warren Heston
Member of Cancer Scientific Advisory Board0yrsno datano data
Philip Livingston
Member of Cancer Scientific Advisory Board0yrsno datano data
Bradley Campbell
Independent Director3.7yrsUS$225.16k0.014% $52.3k
Karen Jean Ferrante
Independent Director6.1yrsUS$222.16kno data
Ann MacDougall
Interim Independent Chair of the Board0.3yrsno datano data

3.7yrs

Average Tenure

64yo

Average Age

Experienced Board: PGP's board of directors are considered experienced (3.7 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 14.5%.


Top Shareholders

Company Information

Progenics Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Progenics Pharmaceuticals, Inc.
  • Ticker: PGP
  • Exchange: DB
  • Founded: 1986
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$407.046m
  • Listing Market Cap: US$376.273m
  • Shares outstanding: 86.42m
  • Website: https://www.progenics.com

Number of Employees


Location

  • Progenics Pharmaceuticals, Inc.
  • One World Trade Center
  • 47th Floor
  • New York City
  • New York
  • 10007
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
PGNXNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDNov 1997
PGPDB (Deutsche Boerse AG)YesCommon StockDEEURNov 1997
0KOALSE (London Stock Exchange)YesCommon StockGBUSDNov 1997

Biography

Progenics Pharmaceuticals, Inc., an oncology company, develops, manufactures, and commercializes pharmaceutical products and other technologies to target, diagnose, and treat cancer in the United States and internationally. The company’s product candidates include Azedra, a radiotherapeutic product candidate for the treatment of iobenguane scan positive, unresectable, and locally advanced or metastatic pheochromocytoma or paraganglioma for adult and pediatric patients; PyL, a clinical-stage fluorinated prostate specific membrane antigen (PSMA)-targeted PET/CT imaging agent for prostate cancer; and 1095, a PSMA-targeted Iodine-131 labeled small molecule, which is in Phase II clinical trial for the treatment of metastatic castration-resistant prostate cancer. Its product candidates also comprise PSMA TTC, a thorium-227 labeled PSMA-targeted antibody therapeutic that is in Phase I clinical trial for treatment of metastatic prostate cancer; and Leronlimab, a humanized monoclonal antibody, which is in Phase III development for the treatment of HIV infection. The company also offers Relistor-subcutaneous injection for the treatment of opioid-induced constipation (OIC) in adults with chronic non-cancer pain or advanced-illness adult patients; Relistor tablets for the treatment of OIC in adults with chronic non-cancer pain; PSMA AI, an imaging analysis technology that uses artificial intelligence and machine learning to quantify and automate the reading of PSMA targeted imaging; and automated bone scan index, a software that quantifies the hotspots on bone scans and calculates the bone scan index value. It has license agreement with Salix Pharmaceuticals, Inc. for the development and commercialization of Relistor worldwide; and Amgen Fremont, Inc. to use its XenoMouse technology for generating human antibodies to PSMA. Progenics Pharmaceuticals, Inc. was founded in 1986 and is based in New York City, New York. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/19 20:59
End of Day Share Price2020/02/19 00:00
Earnings2019/09/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.